Pilot study to analyze COVID-19 vaccination response

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00024787

Enrollment

Registered

2021-05-05

Start date

2021-05-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M05

Interventions

Group 1: Independently performed saliva sampling and capillary blood collection from the upper arm

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Complete SARS-CoV-2 vaccination status - Healthy volunteer or patient with inflammatory disease

Exclusion criteria

Exclusion criteria: The patient is unwilling or unable to participate in the study

Design outcomes

Primary

Measure	Time frame
Comparison of SARS-CoV-2 vaccination response in patients with inflammatory diseases and healthy volunteers at time T0 and T1 (3 months) via measurement of antibody levels. Saliva samples and capillary samples are compared with the gold standard "venous blood samples".	—

Secondary

Measure	Time frame
- Long-term course of the SARS-CoV-2 antibody titer - Analysis of the impact of demographic and clinical parameters - Acceptance and ease of use of the saliva sample and capillary blood collection	—

Countries

Germany

Contacts

Public ContactJohannes Knitza

Medizinische Klinik 3, Universitätsklinikum Erlangen

johannes.knitza@uk-erlangen.de+4991318534742

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026